TY - JOUR
T1 - Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors
T2 - How many genetic subgroups are there?
AU - Vandesompele, Jo
AU - Speleman, Frank
AU - Van Roy, Nadine
AU - Laureys, Genevi Ve
AU - Brinkschmidt, Christian
AU - Christiansen, Holger
AU - Lampert, Fritz
AU - Lastowska, Maria
AU - Bown, Nick
AU - Pearson, Andy
AU - Nicholson, James C.
AU - Ross, Fiona
AU - Combaret, Val Rie
AU - Delattre, Olivier
AU - Feuerstein, Bert G.
AU - Plantaz, Dominique
PY - 2001
Y1 - 2001
N2 - Procedure. Analysis of comparative genomic hybridization (CGH) data of 120 tumors from four different studies, and data of 84 previously unpublished tumors, allowed delineation of at least six different genetic subsets of neuroblastomas. Results and Conclusions. A small number of tumors show no detectable imbalances. A second group of tumors presents with gains and losses of whole chromosomes and is found predominantly in prognostically favorable stage 1 and 2 tumors. The remaining groups are characterized by the presence of partial chromosome imbalances, and are found mostly in stage 3, 4, and 4S tumors. The third group shows 17q gain without 11q loss, 1p loss, or MYCN amplification (MNA). The fourth group has 1p deletion or MNA, and finally, a fifth group shows 11q loss without 1p deletion or MNA, and is found mainly in stage 4 tumors. The latter group is significantly associated with losses of 3p, 4p, and 14q.
AB - Procedure. Analysis of comparative genomic hybridization (CGH) data of 120 tumors from four different studies, and data of 84 previously unpublished tumors, allowed delineation of at least six different genetic subsets of neuroblastomas. Results and Conclusions. A small number of tumors show no detectable imbalances. A second group of tumors presents with gains and losses of whole chromosomes and is found predominantly in prognostically favorable stage 1 and 2 tumors. The remaining groups are characterized by the presence of partial chromosome imbalances, and are found mostly in stage 3, 4, and 4S tumors. The third group shows 17q gain without 11q loss, 1p loss, or MYCN amplification (MNA). The fourth group has 1p deletion or MNA, and finally, a fifth group shows 11q loss without 1p deletion or MNA, and is found mainly in stage 4 tumors. The latter group is significantly associated with losses of 3p, 4p, and 14q.
KW - CGH
KW - Genetic subgroup
KW - Neuroblastoma
UR - http://www.scopus.com/inward/record.url?scp=0035171136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035171136&partnerID=8YFLogxK
U2 - 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E
DO - 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E
M3 - Article
C2 - 11464905
AN - SCOPUS:0035171136
SN - 0098-1532
VL - 36
SP - 5
EP - 10
JO - Medical and Pediatric Oncology
JF - Medical and Pediatric Oncology
IS - 1
ER -